Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes

Frontiers in Neurology
Lior Greenbaum, Bernard Lerer

Abstract

Antipsychotic-induced movement disorders are major side effects of antipsychotic drugs among schizophrenia patients, and include antipsychotic-induced parkinsonism (AIP) and tardive dyskinesia (TD). Substantial pharmacogenetic work has been done in this field, and several susceptibility variants have been suggested. In this paper, the genetics of antipsychotic-induced movement disorders is considered in a broader context. We hypothesize that genetic variants that are risk factors for AIP and TD may provide insights into the pathophysiology of motor symptoms in Parkinson's disease (PD). Since loss of dopaminergic stimulation (albeit pharmacological in AIP and degenerative in PD) is shared by the two clinical entities, genes associated with susceptibility to AIP may be modifier genes that influence clinical expression of PD motor sub-phenotypes, such as age at onset, disease severity, or rate of progression. This is due to their possible functional influence on compensatory mechanisms for striatal dopamine loss. Better compensatory potential might be beneficial at the early and later stages of the PD course. AIP vulnerability variants could also be related to latent impairment in the nigrostriatal pathway, affecting its functiona...Continue Reading

References

Sep 1, 1992·The American Journal of Psychiatry·R YassaM Thibeau
Jan 1, 1992·Schizophrenia Bulletin·R Yassa, D V Jeste
Jun 1, 1991·Lancet·Y Agid
Jun 1, 1988·Journal of Neurology, Neurosurgery, and Psychiatry·R J Hardie, A J Lees
Jan 1, 1997·Schizophrenia Bulletin·T E HansenW F Hoffman
Jan 1, 1997·Schizophrenia Bulletin·M F EganR J Wyatt
Aug 5, 1998·International Clinical Psychopharmacology·T R Barnes, M A McPhillips
Aug 29, 1998·Journal of Neurochemistry·Y Sagara
Oct 2, 1998·Movement Disorders : Official Journal of the Movement Disorder Society·P J BlanchetT N Chase
Nov 13, 1998·The American Journal of Psychiatry·M G WoernerJ M Kane
Jul 13, 2000·Lancet·M J PorrittD W Howells
Apr 1, 1997·Journal of Clinical Psychopharmacology·S AngusN M Schneider
Oct 26, 2000·Brain : a Journal of Neurology·A Schrag, N Quinn
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·J E Ahlskog, M D Muenter
Jun 8, 2001·Movement Disorders : Official Journal of the Movement Disorder Society·P Del DottoU Bonuccelli
Jan 5, 2002·Journal of Neural Transmission·S Hassin-BaerN Giladi
Jan 22, 2002·Clinical Neuropharmacology·O Rascol, N Fabre
May 16, 2002·British Journal of Pharmacology·Pattipati S NaiduShrinivas K Kulkarni
Apr 15, 2003·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Pierre J Blanchet
Sep 16, 2003·Neuron·William Dauer, Serge Przedborski
Jan 1, 1959·The American Journal of Psychiatry·F A FREYHAN
Mar 25, 1961·JAMA : the Journal of the American Medical Association·F J AYD
Mar 24, 2004·Trends in Neurosciences·Jose A ObesoManuel Rodriguez Diaz
May 4, 2004·The American Journal of Psychiatry·Anil K MalhotraJames L Kennedy
Nov 20, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Mariese A HelyRobert Trafficante
Apr 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Joseph Jankovic
Jun 7, 2005·Trends in Pharmacological Sciences·Nicola Biagio Mercuri, Giorgio Bernardi
Sep 15, 2005·Archives of Internal Medicine·Paula A RochonJerry H Gurwitz
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 27, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Mordechai LorberboymRuth Djaldetti
Nov 3, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseRobert Miller
Mar 21, 2006·Lancet Neurology·Anette Schrag, Jonathan M Schott
Aug 18, 2006·Lancet Neurology·Ruth DjaldettiEldad Melamed

❮ Previous
Next ❯

Methods Mentioned

BETA
SGA
genotyping
exome sequencing

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.